14th Annual University of Pennsylvania Conference on statistical issues in clinical trials/subgroup analysis in clinical trials: Opportunities and challenges (afternoon panel discussion)

TY - JOUR

T1 - 14th Annual University of Pennsylvania Conference on statistical issues in clinical trials/subgroup analysis in clinical trials

T2 - Opportunities and challenges (afternoon panel discussion)

AU - Imai, Kosuke

AU - Rosenblum, Michael

AU - Rothmann, Mark

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: M.R. was supported by the Johns Hopkins Center of Excellence in Regulatory Science and Innovation, which is funded by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (grant no. U01FD005942). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by any of the aforementioned organizations, the FDA/HHS, nor the U.S. Government. The other author(s) declared no receipt of financial support for the research, authorship, and/or publication of this article. Funding Information: The authors thank their professional society sponsors the Society for Clinical Trials, the American Statistical Association, and the National Institute of Statistical Sciences whose structural support has been invaluable for the success of this conference. Members of the program committee include Drs Susan S. Ellenberg, Jonas H. Ellenberg, Mary Putt, Pam Shaw (currently at Kaiser Permanente Washington Health Research Institute), Alisa J. Stephens-Shields, and James Lewis in the Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: M.R. was supported by the Johns Hopkins Center of Excellence in Regulatory Science and Innovation, which is funded by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (grant no. U01FD005942). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by any of the aforementioned organizations, the FDA/HHS, nor the U.S. Government. The other author(s) declared no receipt of financial support for the research, authorship, and/or publication of this article.

PY - 2023/8

Y1 - 2023/8

UR - http://www.scopus.com/inward/record.url?scp=85159000793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159000793&partnerID=8YFLogxK

U2 - 10.1177/17407745231169681

DO - 10.1177/17407745231169681

M3 - Comment/debate

C2 - 37148213

AN - SCOPUS:85159000793

SN - 1740-7745

VL - 20

SP - 405

EP - 415

JO - Clinical Trials

JF - Clinical Trials

IS - 4

ER -